-
Something wrong with this record ?
Frequent intravenous pulses of growth hormone together with alanylglutamine supplementation in prolonged critical illness after multiple trauma: effects on glucose control, plasma IGF-I and glutamine
F Duska, M Fric, J Pazout, P Waldauf, P Tuma, J Pachl
Language English Country Great Britain
Document type Randomized Controlled Trial
Grant support
NR8230
MZ0
CEP Register
Digital library NLK
Full text - Část
Source
- MeSH
- Dipeptides administration & dosage MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Financing, Organized MeSH
- Glutamine blood MeSH
- Insulin-Like Growth Factor I analysis MeSH
- Blood Glucose metabolism MeSH
- Critical Illness MeSH
- Middle Aged MeSH
- Humans MeSH
- Multiple Trauma drug therapy MeSH
- Growth Hormone administration & dosage MeSH
- Drug Administration Routes MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Randomized Controlled Trial MeSH
OBJECTIVE: We aim to demonstrate that low dose growth hormone (GH) administered in i.v. pulses every 3h is able to normalize IGF-I levels in subjects with prolonged critical illness, after multiple trauma. We also ask whether it is possible to control glycaemia during such a treatment and how alanylglutamine (AG) supplementation influences plasma glutamine concentration. METHODS: We used a prospective double-blind (group 1 vs. 2), randomized trial with an open-label control arm (group 3). Thirty multiple trauma patients (median age: 36, 42, 46 years) were randomized on day 4 after trauma to receive (group 1, n=10) i.v. AG supplementation (0.3 g/kg day from day 4 till 17) and i.v. GH (0.05 mg/kg day divided into 8 boluses, maximum dose at 3 AM, administered on days 7-17) or AG and placebo (group 2, n=10). Group 3 (n=10) received isocaloric isonitrogenous (proteins 1.5 g/kg day) nutrition without AG. Glycaemia was controlled by i.v. insulin infusion according to a routine protocol. RESULTS: GH treatment caused an increase of IGF-I (from median 169 on day 4 to 493 ng/ml on day 17), IGFBP-3 (from 2.4 to 3.2 microg/ml) and a fall in IGFBP-1 (from 11.5 to 3.1 microg/ml), whilst in both groups 2 and 3 these indices remained unchanged. At the end of the study (day 17) IGF-I and IGFBP-1 differed significantly among groups (p=0.008 resp. p=0.010, Kruskal-Wallis). Plasma glutamine remained below the normal range through the study in all groups (median: 0.18-0.30 mM), but had a tendency to rise in group 2 in contrast with a fall in groups 1 and 3 (NS). Group 1 required more insulin (p<0.01) than did the control group but median glycaemia was only 0.4-0.5 mM higher in group 1 (6.5 mM) than in groups 2 and 3 (6.1 resp. 6.0 mM). CONCLUSIONS: GH (0.05 g/kg day) administered in i.v. pulses is able to normalize IGF-I levels in subjects with prolonged critical illness after trauma. During this treatment, the standard dose of AG prevents worsening of plasma glutamine deficiency and glucose control is possible using routine algorithms, but it requires higher insulin doses.
- 000
- 02103naa 2200433 a 4500
- 001
- bmc11003022
- 003
- CZ-PrNML
- 005
- 20131002105020.0
- 008
- 110225s2008 xxk e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Duška, František, $d 1976- $7 mzk2007386027
- 245 10
- $a Frequent intravenous pulses of growth hormone together with alanylglutamine supplementation in prolonged critical illness after multiple trauma: effects on glucose control, plasma IGF-I and glutamine / $c F Duska, M Fric, J Pazout, P Waldauf, P Tuma, J Pachl
- 314 __
- $a Department of Anaesthesia and Critical Care Medicine, Charles University, 3rd Faculty of Medicine, Srobarova 50, Prague, Czech Republic. fduska@yahoo.com
- 520 9_
- $a OBJECTIVE: We aim to demonstrate that low dose growth hormone (GH) administered in i.v. pulses every 3h is able to normalize IGF-I levels in subjects with prolonged critical illness, after multiple trauma. We also ask whether it is possible to control glycaemia during such a treatment and how alanylglutamine (AG) supplementation influences plasma glutamine concentration. METHODS: We used a prospective double-blind (group 1 vs. 2), randomized trial with an open-label control arm (group 3). Thirty multiple trauma patients (median age: 36, 42, 46 years) were randomized on day 4 after trauma to receive (group 1, n=10) i.v. AG supplementation (0.3 g/kg day from day 4 till 17) and i.v. GH (0.05 mg/kg day divided into 8 boluses, maximum dose at 3 AM, administered on days 7-17) or AG and placebo (group 2, n=10). Group 3 (n=10) received isocaloric isonitrogenous (proteins 1.5 g/kg day) nutrition without AG. Glycaemia was controlled by i.v. insulin infusion according to a routine protocol. RESULTS: GH treatment caused an increase of IGF-I (from median 169 on day 4 to 493 ng/ml on day 17), IGFBP-3 (from 2.4 to 3.2 microg/ml) and a fall in IGFBP-1 (from 11.5 to 3.1 microg/ml), whilst in both groups 2 and 3 these indices remained unchanged. At the end of the study (day 17) IGF-I and IGFBP-1 differed significantly among groups (p=0.008 resp. p=0.010, Kruskal-Wallis). Plasma glutamine remained below the normal range through the study in all groups (median: 0.18-0.30 mM), but had a tendency to rise in group 2 in contrast with a fall in groups 1 and 3 (NS). Group 1 required more insulin (p<0.01) than did the control group but median glycaemia was only 0.4-0.5 mM higher in group 1 (6.5 mM) than in groups 2 and 3 (6.1 resp. 6.0 mM). CONCLUSIONS: GH (0.05 g/kg day) administered in i.v. pulses is able to normalize IGF-I levels in subjects with prolonged critical illness after trauma. During this treatment, the standard dose of AG prevents worsening of plasma glutamine deficiency and glucose control is possible using routine algorithms, but it requires higher insulin doses.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a krevní glukóza $x metabolismus $7 D001786
- 650 _2
- $a kritický stav $7 D016638
- 650 _2
- $a dipeptidy $x aplikace a dávkování $7 D004151
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a způsoby aplikace léků $7 D004333
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glutamin $x krev $7 D005973
- 650 _2
- $a růstový hormon $x aplikace a dávkování $7 D013006
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a insulinu podobný růstový faktor I $x analýza $7 D007334
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a polytrauma $x farmakoterapie $7 D009104
- 650 _2
- $a financování organizované $7 D005381
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Fric, Michal. $7 xx0241106
- 700 1_
- $a Pažout, Jaroslav $7 xx0137181
- 700 1_
- $a Waldauf, Petr $7 xx0085547
- 700 1_
- $a Tůma, Petr $7 xx0105786
- 700 1_
- $a Pachl, Jan, $d 1949- $7 nlk19990073644
- 773 0_
- $t Growth Hormone & Igf Research $w MED00005163 $g Roč. 18, č. 1 (2008), s. 82-87 $x 1096-6374
- 910 __
- $a ABA008 $b x $y 1
- 990 __
- $a 20110413114001 $b ABA008
- 991 __
- $a 20131002105537 $b ABA008
- 999 __
- $a ok $b bmc $g 830425 $s 695014
- BAS __
- $a 3
- BMC __
- $a 2008 $b 18 $c 1 $d 82-87 $i 1096-6374 $m Growth hormone & IGF research $n Growth Horm IGF Res $x MED00005163
- GRA __
- $a NR8230 $p MZ0
- LZP __
- $a 2011-2B/dkme